Welcome to our dedicated page for Contineum Therapeutics SEC filings (Ticker: CTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Contineum Therapeutics, Inc. (CTNM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biopharmaceutical issuer. Contineum files current reports on Form 8-K to describe material events such as clinical data readouts, financing transactions, shareholder votes and trial design updates, alongside its other periodic SEC reports.
For CTNM, clinical development milestones are a recurring theme in its filings. Form 8-K reports have summarized topline data from the PIPE-307 Phase 2 VISTA trial in relapsing-remitting multiple sclerosis and positive topline data from the PIPE-791 Phase 1b PET trial assessing LPA1 receptor occupancy in healthy volunteers and progressive multiple sclerosis patients. Another 8-K details the design of a 26-week, international, randomized, double-blind, placebo-controlled Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, including its primary efficacy measure based on change in forced vital capacity.
Filings also document capital markets activity. Contineum has reported entering into an underwriting agreement for an upsized public offering of its Class A common stock under a shelf registration statement on Form S-3, as well as prior at-the-market offerings. These disclosures outline the terms of offerings, estimated net proceeds and related exhibits such as underwriting agreements and legal opinions.
Investors can use this page to review CTNM’s governance and shareholder matters, including results of its annual meeting of stockholders reported on Form 8-K, where director elections and auditor ratification votes are recorded. With real-time updates from EDGAR and AI-powered summaries, this filings page helps readers quickly understand the key points in Contineum’s 8-Ks and related exhibits, while still allowing full-text access to the underlying SEC documents for deeper analysis.
Contineum Therapeutics reported Q1 2026 results showing a net loss of $14.5 million, slightly improved from $16.0 million a year earlier, as it continues investing in its neuroscience, inflammation and immunology pipeline.
Research and development expenses were $11.6 million, down from $13.7 million, mainly as trials for PIPE-307 and earlier PIPE-791 studies wound down, partly offset by spending on the new Phase 2 IPF trial for PIPE-791. General and administrative costs rose to $5.3 million, driven largely by higher stock-based compensation and headcount.
Cash, cash equivalents and marketable securities totaled $246.3 million as of March 31, 2026, and management believes this will fund operations for at least 12 months. The company amended its at-the-market program to allow up to $100.0 million of additional Class A share sales but did not use it in the quarter. Contineum highlighted positive Phase 1b chronic pain data for PIPE-791 and ongoing collaboration with J&J on PIPE-307, including J&J’s Phase 2 Moonlight-1 depression trial.
Contineum Therapeutics reported first-quarter 2026 results, highlighting clinical progress and a strengthened financial position. The company recently announced positive topline data from an exploratory Phase 1b trial of PIPE-791 for chronic osteoarthritis or low back pain, which met its safety and tolerability objective and showed numerically greater pain improvements versus placebo. It also began patient dosing in PROPEL-IPF, a 26-week global Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, and Johnson & Johnson is running the Phase 2 Moonlight-1 trial of PIPE-307/JNJ-89495120 in major depressive disorder.
Cash, cash equivalents and marketable securities totaled $246.3 million as of March 31, 2026, and the company expects its cash runway to extend through mid-2029. Research and development expenses were $11.6 million, a 15 percent decrease from the first quarter of 2025, while general and administrative expenses were $5.3 million, a 20 percent increase. Net loss was $14.5 million for the quarter, compared with $16.0 million a year earlier, or $0.39 per share based on 37,339,026 weighted-average shares outstanding.
Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported open-market sales of company stock. On May 1, 2026, he sold a total of 4,170 shares of Class A Common Stock in two transactions at weighted average prices of $13.06 and $13.84 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025.
After these sales, he holds 143,542 shares directly and 6,842 shares indirectly through his spouse. The prices reflect multiple trades within reported ranges between $12.69 and $13.86 per share.
CTNM affiliate reported planned sales of Common Stock via Form 144. The filing lists multiple 10b5-1 programmed sales by Daniel Lorrain on several dates in 2026, including trades of 4,170, 3,824, 4,300, and other share amounts with indicated proceeds per trade. The filing names Morgan Stanley Smith Barney LLC as the broker and shows the securities type as Restricted Stock Units dated 05/09/2017.
Contineum Therapeutics, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 26, 2026 at 8:00 a.m. Pacific Time via webcast after advance registration at www.proxydocs.com/CTNM.
Stockholders will vote on electing three Class II directors—Evert Schimmelpennink, Lori M. Lyons‑Williams and Diego Miralles, M.D.—to serve until the 2029 annual meeting, and on ratifying Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Only holders of the 32,723,877 shares of Class A common stock outstanding as of April 27, 2026 may vote, with one vote per share. The board recommends voting “FOR” all director nominees and “FOR” auditor ratification.
Contineum Therapeutics reported positive topline data from an exploratory Phase 1b trial of PIPE-791, an oral, once-daily 10 mg LPA1 receptor antagonist, in chronic osteoarthritis pain (COAP) and chronic low back pain (CLBP). The randomized, double-blind, placebo-controlled, 4‑week crossover study enrolled 43 patients, split between COAP and CLBP.
The trial met its primary objective of assessing safety and tolerability, with no serious adverse events reported and most treatment-emergent events, such as headache and fatigue, described as mild to moderate. Vital signs, including blood pressure and orthostatic measures, showed no clinically meaningful changes.
Exploratory efficacy measures using the 11‑point Pain‑Intensity Numerical Rating Scale showed that patients receiving PIPE-791 generally had greater numerical improvements in average and worst daily pain than those on placebo, particularly in the COAP group. Additional exploratory endpoints, including the proportion of patients achieving at least a 30% pain reduction and a modified knee osteoarthritis function scale, were described as supporting the positive pain findings. Management stated that these results support further evaluation of PIPE-791 for chronic pain.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported shared beneficial ownership of 1,658,349 shares of Contineum Therapeutics, Inc. Class A common stock, representing 5.1% of that class. The filing is a joint Schedule 13G and includes a Joint Filing Agreement dated April 16, 2026.
The filing states the disclosed shares are held by entities subject to voting and investment control by Millennium Management LLC and related managers; the filing does not assert sole voting or sole dispositive power.
Contineum Therapeutics’ Chief Scientific Officer Daniel S. Lorrain reported an open-market sale of 4,170 shares of Class A Common Stock. The shares were sold at a weighted average price of $13.4326 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025.
After the sale, he directly holds 147,712 shares. In addition, 6,842 shares are held indirectly by his spouse. The sale price reflected multiple trades within a range of $13.08 to $13.60 per share.
Daniel Lorrain submitted a Form 144 notice to sell 914 Restricted Stock Units of Common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists multiple recent 10b5-1 sales by the same person, including 03/02/2026 (4,170 shares for $62,585.03) and 02/24/2026 (4,300 shares for $68,936.04).
The securities to be sold are described as Restricted Stock Units dated 05/09/2017. The broker/agent is shown as Morgan Stanley Smith Barney LLC on Nasdaq-listed securities, and the filing records transaction history in the prior three months under a 10b5-1 plan.